US › Healthcare

Eupraxia Pharmaceuticals Inc. Common Stock (EPRX)

US · Healthcare · Biotechnology

$8.38+3.58%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-14.5M

EPS

$-0.23

EPS estimate

$-0.25

EPS came in at -0.23 against a street estimate of -0.25 — a beat of 8.0%.

Key statistics

Market cap

$535.9M

Forward P/E

0.0

P/B

4.92

Book value

$1.55

EPS (TTM)

$-1.02

52-week high

$9.32

52-week low

$5.16

50-day MA

$6.83

200-day MA

$7.18

Beta

1.49

Analyst view

with an average price target of $16.35.

Shareholding

Insiders

13.98%

Institutions

43.16%

Largest institutional holders

Fund	Stake
Beutel, Goodman & Company Ltd.	5.55%
Affinity Asset Advisors, LLC	2.50%
Vivo Capital, LLC	2.04%
Balyasny Asset Management LLC	2.04%
Scotia Capital Inc	2.03%
Ikarian Capital, LLC	1.84%
Partner Fund Management LP	1.83%
Great Point Partners LLC	1.82%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eupraxia Pharmaceuticals Inc. Common Stock — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.